Tumor-specific PD-L1 upregulation may be driven by pro-survival pathways such as MAPK and PI3K/Akt, as well as transcription factors such as HIF-1, STAT3 and NF-ĸB 10-12. This evidence concerns the gene CD274 and neoplasm.